Direct Thrombin Inhibitors
Direct Thrombin Inhibitors - Related Videos
01:25
Antihypertensive Drugs: Direct Renin Inhibitors
0 Views •
2024
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
08:01
The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
0 Views •
2026
This protocol describes the Nijmegen Hemostasis Assay, which enables simultaneous, time-resolved measurement of thrombin and plasmin generation to provide an integrated assessment of coagulation and fibrinolysis. The assay aims to improve characterization of hemostatic balance in research and clinical settings beyond the scope of conventional hemostatic tests.
18:30
RNA-seq Analysis of Transcriptomes in Thrombin-treated and Control Human Pulmonary Microvascular Endothelial Cells
0 Views •
Cited by 12 •
2013
This protocol presents a complete and detailed procedure to apply RNA-seq, a powerful next-generation DNA sequencing technology, to profile transcriptomes in human pulmonary microvascular endothelial cells with or without thrombin treatment. This protocol is generalizable to various cells or tissues affected by different reagents or disease states.
01:52
Eukaryotic Transcription Inhibitors
0 Views •
2020
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells. Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
04:00
Modelling Intratumoral Treatment with miRNA Inhibitors: A Method to Analyze the Effect of miRNA Inhibitors on Tumor Growth in Murine Model
0 Views •
2023
This video demonstrates the in vivo delivery of miRNA inhibitors as therapeutic agents against tumor growth in orthotopic mouse models. The intratumoral administration of synthetic miRNA inhibitors or antagomiRs allows them to bind and inhibit endogenous miRNAs, thereby causing mRNA upregulation and suppression of tumor growth.
FAQs
By occupying thrombin’s active site, these drugs prevent thrombin from converting fibrinogen into fibrin, a key structural component of a clot. This interrupts clot propagation rather than acting indirectly through another coagulation protein. The result is reduced clot formation, which explains their role in pharmacologic prevention and treatment of venous thromboembolism.
Direct thrombin inhibitors act without requiring antithrombin as a cofactor. That feature distinguishes their mechanism from anticoagulant strategies that depend on antithrombin-mediated inhibition. In pharmacology, this independence helps explain why they can serve as alternatives when heparin is unsuitable, particularly in the setting of suspected or confirmed heparin-induced thrombocytopenia.
Blocking thrombin also limits thrombin-mediated platelet activation. This gives the drugs an effect beyond reducing fibrin production, because thrombin contributes both to clot structure and to platelet-driven amplification of coagulation. Considering these two actions helps explain why inhibition of thrombin can reduce clot formation through complementary effects within the coagulation response.
Argatroban and bivalirudin are parenteral direct thrombin inhibitors, so they are suited to situations requiring administered anticoagulation, including when heparin cannot be used. Dabigatran is an oral agent that supports longer-term anticoagulation. This difference in route and treatment duration helps match the drug choice to the clinical or procedural context.
Parenteral agents such as argatroban and bivalirudin are especially useful when heparin is unsuitable. The overview identifies suspected or confirmed heparin-induced thrombocytopenia as a key setting for their use. Their role is therefore not limited to routine anticoagulation; they provide an alternative approach when exposure to heparin creates an important clinical concern.
As an oral direct thrombin inhibitor, dabigatran provides a way to continue anticoagulation over a longer period without relying on a parenteral route. The overview places it in prevention and treatment contexts that include venous thromboembolism and stroke prevention in selected patients with atrial fibrillation. Its application is therefore associated with ongoing rather than primarily procedural anticoagulation.
These drugs support several pharmacologic goals: preventing or treating venous thromboembolism, reducing stroke risk in selected patients with atrial fibrillation, and providing anticoagulation during procedures. The appropriate agent depends partly on whether the situation calls for parenteral or oral treatment and whether heparin is suitable. This range makes thrombin inhibition relevant across preventive, therapeutic, and procedural care.